"First Investment" completed | Xiamen cardiovascular industry fund strategically invests in TRULIVE to accelerate the construction of an industrial synergistic innovation ecosystem
On September 9, the signing ceremony for the 2025 Xiamen Cardiovascular Industry Cooperation Project was successfully held at the main venue of the 25th China International Fair for Investment and Trade. TRULIVE, the first investment project of the Xiamen Cardiovascular Industry Fund, officially signed and settled. The Cardiovascular Industry Fund, in collaboration with Xiamen Industrial Investment and its affiliated funds, strategically invested tens of millions of yuan. The focus is to support TRULIVE in establishing an R&D innovation center, professional education, and marketing center in Xiamen, accelerating the research and development and commercialization process of innovative products for structural heart disease.
Xiamen Cardiovascular Industry Fund, initiated by Xiamen Industrial Investment and Xiamen Venture Capital under the Jin Yuan Group in collaboration with Xiamen Heart Hospital (affiliated with Xiamen University, abbreviated as "Xiamen Heart"), with in-depth cooperation from Xiamen Torch High-tech Industrial Zone and Haicang Investment Zone, is the first public hospital-participated equity investment fund in China focusing on the cardiovascular medical industry. With an initial scale of 200 million yuan, it primarily invests in early-stage projects in fields like innovative cardiovascular devices and diagnostic technologies, establishing an innovation incubation system driven by "professional judgment + investment." The fund represents Xiamen's significant innovative practice using "fiscal policy + financial tools" to explore the integration of medicine and engineering while supporting public welfare. By fully integrating the advantages of government industrial guidance funds, national regional medical centers, and national-level industrial parks, it achieves a closed-loop of "government guidance—capital empowerment—clinical validation—industrial implementation," creating a collaborative platform that integrates governance, industry, academia, research, medicine, capital, and application.
Since its establishment, the fund has always focused on the frontier of cardiovascular healthcare, committed to building a full lifecycle empowerment system for high-quality projects. This round of strategic investment in TRULIVE is a vivid embodiment of the fund's strategic positioning and core value.
During the product development phase
Xiamen Heart Hospital's expert team and the company's R&D team have deeply integrated medical and engineering expertise, jointly tackling challenges related to mitral and tricuspid valve devices. They have been fully involved in the process from device structural design to functional implementation, significantly shortening the technology transformation cycle. In February this year, TRULIVE's transcatheter mitral valve clip system successfully gained approval for market launch, becoming the first domestically produced "linear-type" mitral valve clip.
In the clinical validation stage
Xiamen Heart Hospital experts deeply intervened as "users are optimizers," validating and providing feedback on devices in real clinical scenarios. They proposed crucial clinical suggestions for product performance optimization, facilitating product iteration and upgrades, ultimately gaining recognition from the market and investment institutions.
In the industrial implementation phase
Xiamen Torch High-tech Zone provides TRULIVE with customized carriers and one-stop supporting services, assisting it in establishing a high-standard R&D innovation center, professional education, and marketing center in Xiamen. This investment not only provides capital support but also deepens future industrial synergy between the two parties through the fund as a link. Together, they will promote the innovative R&D, market education, and commercial promotion of valve interventional treatment devices, injecting innovative vitality into the development of Xiamen's cardiovascular health industry.
Investment Incubation for Medical Technology Projects
Provided a replicable and promotable "Xiamen Model"
From innovative incubation at the R&D end, to practical refinement at the clinical end, and then to ecosystem construction at the industrial end, TRULIVE's medical project fully represents the "technology + clinical + capital + industry" four-dimensional empowerment loop of the cardiovascular industry fund, also providing a replicable and promotable "Xiamen Model" for the investment and incubation of medical technology projects.
Wang Bin, Vice President of Xiamen Heart Hospital:
"Clinical-Research-Capital-Industry"
Innovative Practice of Full-Chain Collaboration
Xiamen Heart Hospital Always Adheres to Clinical Needs as the Driving Force, Exploring New Paths for the Integrated Development of Medicine and Engineering, and Fully Serving the High-Quality Development of the Biomedical Industry. The Investment Implementation of TRULIVE is an Innovative Practice of Xiamen Cardiovascular Industry Fund’s Full-Chain Collaboration: "Clinical - R&D - Capital - Industry". We Look Forward to Continuing to Collaborate with All Parties in the Future, Jointly Building and Perfecting the Cardiovascular Health Industry Ecosystem, and Cultivating More "Xiamen-Made" Cardiovascular Innovation Products and Solutions on This Hotbed of Innovation and Entrepreneurship in Xiamen.
TRULIVE Chairman Wen Jing:
For the high-end medical device innovation field in Xiamen
Contribute to Rapid Development
The development of TRULIVE is inseparable from the support of Xiamen. Since 2021, it has received multiple rounds of investment from Xiamen C&D Emerging Investment. Last year, it gained the backing of Xiamen Torch High-Tech Investment, and this year, it received a new round of support from Xiamen Cardiovascular Industry Fund and Xiamen Industrial Investment. Ultimately, under the promotion of various shareholders in Xiamen, TRULIVE successfully established its long-planned R&D, education, and marketing center in Xiamen. This not only marks a historic upgrade in TRULIVE's medical industry R&D system but also serves as a key engine for the company’s "Rooted in China, Facing the World" overall strategy implementation. This collaboration will also provide TRULIVE Medical with a new opportunity to further implement professional education, expand market space, and deepen industrial layout. The project benefits from Xiamen's superior business environment and biomedicine industry foundation. In the future, the company will further rely on Xiamen's industrial and geographical advantages, continue to deepen the cooperation between medicine and engineering, promote the deep integration of clinical practice and scientific research innovation, accelerate technological breakthroughs and achievement transformation, and contribute to the rapid development of Xiamen's high-end medical device innovation field.
Relevant responsible persons from Xiamen Industrial Investment and Xiamen Venture Capital:
Promote Technological and Industrial Innovation
Building a New Paradigm for Industry-Finance Integration
At present, long-term capital and patient capital represented by state-owned assets are becoming an important force in promoting technological innovation and fostering new quality productive forces. Against this backdrop, Xiamen Industrial Investment, as a municipal industrial investment platform, and Xiamen Venture Capital, as a local venture capital institution and the manager of the cardiovascular industry fund, are delighted to collaborate with Xiamen Heart Hospital (Xiaxin Hospital) to implement the guiding principles of General Secretary Xi Jinping on "deeply integrating scientific and industrial innovation," and to establish a new paradigm for the integration of industry and finance. TRULIVE is a leading domestic platform enterprise focused on addressing structural heart diseases. Its product performance has been recognized by Xiaxin Hospital, and its market value acknowledged by investment institutions. We look forward to TRULIVE achieving even greater success after its establishment, and we also anticipate more high-quality innovative enterprises choosing Xiamen as their base.
The event also featured a signing ceremony for industrial cooperation projects, including investment intention agreements for cardiovascular industry funds with Puluo Medical and Life Shield Medical, strategic cooperation agreements between Xiamen Heart Hospital (Xiaxin) and Shukun Technology, Bareun Medical, and Pulu Medical, as well as a strategic partnership agreement between Xiaxin Health Technology and ITG Innovation Leadership.
TRULIVE was founded in 2019 as a cardiovascular interventional platform enterprise specializing in solving blood flow issues. It is committed to developing product technologies that better align with the anatomical and pathological characteristics of Chinese patients. The company has created a one-stop toolbox for cardiovascular treatment, proposing solutions for various blood flow problems in the cardiovascular system, including valve management — treatment of valvular heart disease to ensure proper blood flow direction; clearance — treatment of vascular stenosis or occlusion to ensure smooth blood flow; and shunting — intervention for heart failure to alleviate pathological high pressure. Currently, the company is advancing multiple core products simultaneously. TRULIVE possesses three comprehensive technology platforms: stents, pericardium, and catheters. It has also made strategic deployments in transcatheter mitral valve, tricuspid valve, aortic valve replacement products, and full-range repair products, making it the first domestic company to comprehensively cover the four major golden tracks with substantial progress achieved in core products.